Coexistence of EGFR T790M mutation and common activating mutations in pretreatment non-small cell lung cancer: A systematic review and meta-analysis

被引:59
作者
Chen, Li-Yang [1 ]
Molina-Vila, Miguel A. [2 ]
Ruan, Sheng-Yuan [1 ]
Su, Kang-Yi [3 ]
Liao, Wei-Yu [1 ]
Yu, Kai-Lun [1 ]
Ho, Chao-Chi [1 ]
Shih, Jin-Yuan [1 ]
Yu, Chong-Jen [1 ]
Yang, James Chih-Hsin [4 ,5 ]
Rosell, Rafael [6 ]
Yang, Pan-Chyr [7 ]
机构
[1] Natl Taiwan Univ Hosp, Dept Internal Med, 7 Chung Shan South Rd, Taipei 100, Taiwan
[2] Pangaea Biotech SL, Breakthrough Canc Res Unit, Sabino Arana 5-19, Barcelona 08028, Spain
[3] Natl Taiwan Univ, Coll Med, Dept Clin Lab Sci & Med Biotechnol, 1 Chang Te St, Taipei 100, Taiwan
[4] Natl Taiwan Univ, Coll Med, Grad Inst Oncol, 7 Chung Shan South Rd, Taipei 100, Taiwan
[5] Natl Taiwan Univ, Coll Med, Canc Res Ctr, 7 Chung Shan South Rd, Taipei 100, Taiwan
[6] Hosp Germans Trias i Pujol, Catalan Inst Oncol, Canc Biol & Precis Med Program, Ctra Canyet S-N, Badalona 08916, Spain
[7] Natl Taiwan Univ, 1 Roosevelt Rd Sec 4, Taipei 100, Taiwan
关键词
Non-small cell lung cancer; Epidermal growth factor receptor; T790M; L858R; Exon; 19; deletions; Meta-analysis; GROWTH-FACTOR-RECEPTOR; TYROSINE-KINASE INHIBITOR; OPEN-LABEL; PHASE-III; 1ST-LINE TREATMENT; ASIAN PATIENTS; EXON; 19; ADENOCARCINOMA; GEFITINIB; SURVIVAL;
D O I
10.1016/j.lungcan.2016.01.019
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: Previous studies have indicated that EGFR exon 19 deletions in non-small cell lung cancer (NSCLC) are associated with better outcomes to tyrosine kinase inhibitors (TKIs) than the L858R mutation. This study aimed to evaluate whether T790M, a resistant mutation, is more likely to coexist with L858R mutation than with exon 19 deletions in pretreatment NSCLC patients. Materials and method: We searched MEDLINE and EMBASE up to Nov 30th, 2015 to identify randomized controlled trials (RCTs) and observational studies that reported pretreatment T790M and EGFR-activating mutation. A meta-analysis was performed using a random-effects model. The primary outcome was odds ratio (OR) of pretreatment T790M mutation in NSCLC co-existing with L858R mutation and exon 19 deletions. Stratified analysis was performed based on sensitivity of mutation detection methods for T790M. Results: We identified 15 observational studies and 3 RCTs for analysis. Pretreatment T790M was more frequent in L858R than in exon 19 mutated patients. The association of T790M and L858R was statistically significant in observational studies (OR, 1.65, 95% CI, 1.17-2.32), with less precision in Ras (OR, 1.84, 95% CI, 0.96-3.52). In the stratified analysis based on the sensitivity of the mutation detection methods, the association was observed in the studies using intermediately (detection limit <5% and >= 0.1%; OR, 2.23, 95% CI, 1.19-4.17) and highly sensitive methods (detection limit <0.1%; OR, 1.74, 95% CI, 1.10-2.73), but not in those using low sensitivity methods (detection limit >5%; OR, 1.28, 95% CI, 0.74-2.23). Conclusions: Pretreatment EGFR T790M mutation is more likely to coexist with L858R mutation than with exon 19 deletions in NSCLC. This association was observed only in studies using sensitive mutation detection methods (<5%). (C) 2016 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:46 / 53
页数:8
相关论文
共 43 条
[1]  
[Anonymous], J MED CHEM
[2]  
[Anonymous], FUTURE ONCOL
[3]  
[Anonymous], J CLIN ONCOL
[4]  
[Anonymous], J CLIN PATHOL
[5]   The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell lung cancer [J].
Arrieta, Oscar ;
Felipe Cardona, Andres ;
Corrales, Luis ;
Delia Campos-Parra, Alma ;
Sanchez-Reyes, Roberto ;
Amieva-Rivera, Eduardo ;
Rodriguez, July ;
Vargas, Carlos ;
Carranza, Hernan ;
Otero, Jorge ;
Karachaliou, Nikki ;
Astudillo, Horacio ;
Rosell, Rafael .
LUNG CANCER, 2015, 87 (02) :169-175
[6]   Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small cell lung cancer except both exon 19 deletion and exon 21 L858R: A retrospective analysis in Korea [J].
Baek, Jin Ho ;
Sun, Jong-Mu ;
Min, Young Joo ;
Cho, Eun Kyung ;
Cho, Byoung Chul ;
Kim, Joo-Hang ;
Ahn, Myung-Ju ;
Park, Keunchil .
LUNG CANCER, 2015, 87 (02) :148-154
[7]   The Impact of EGFR T790M Mutations and BIM mRNA Expression on Outcome in Patients with EGFR-Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial [J].
Costa, Carlota ;
Molina, Miguel Angel ;
Drozdowskyj, Ana ;
Gimenez-Capitan, Ana ;
Bertran-Alamillo, Jordi ;
Karachaliou, Niki ;
Gervais, Radj ;
Massuti, Bartomeu ;
Wei, Jia ;
Moran, Teresa ;
Majem, Margarita ;
Felip, Enriqueta ;
Carcereny, Enric ;
Garcia-Campelo, Rosario ;
Viteri, Santiago ;
Taron, Miquel ;
Ono, Mayumi ;
Giannikopoulos, Petros ;
Bivona, Trever ;
Rosell, Rafael .
CLINICAL CANCER RESEARCH, 2014, 20 (07) :2001-2010
[8]   The predictive role of pretreatment epidermal growth factor receptor T790M mutation on the progression-free survival of tyrosine-kinase inhibitor-treated non-small cell lung cancer patients: a meta-analysis [J].
Ding, Ding ;
Yu, Yongfeng ;
Li, Ziming ;
Niu, Xiaomin ;
Lu, Shun .
ONCOTARGETS AND THERAPY, 2014, 7 :387-393
[9]   Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer [J].
Eck, Michael J. ;
Yun, Cai-Hong .
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS, 2010, 1804 (03) :559-566
[10]   Highly Sensitive Detection of EGFR T790M Mutation Using Colony Hybridization Predicts Favorable Prognosis of Patients with Lung Cancer Harboring Activating EGFR Mutation [J].
Fujita, Yoshihiko ;
Suda, Kenichi ;
Kimura, Hideharu ;
Matsumoto, Kazuko ;
Arao, Tokuzo ;
Nagai, Tomoyuki ;
Saijo, Nagahiro ;
Yatabe, Yasushi ;
Mitsudomi, Tetsuya ;
Nishio, Kazuto .
JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) :1640-1644